{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T12:07:15Z","timestamp":1792670835964,"version":"4.5.0"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2013,7,1]],"date-time":"2013-07-01T00:00:00Z","timestamp":1372636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2013,7,1]],"date-time":"2013-07-01T00:00:00Z","timestamp":1372636800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1007\/s40265-013-0079-2","type":"journal-article","created":{"date-parts":[[2013,7,9]],"date-time":"2013-07-09T07:17:21Z","timestamp":1373354241000},"page":"1147-1155","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Meningococcal Vaccines: Current Issues and Future Strategies"],"prefix":"10.1007","volume":"73","author":[{"given":"Amanda C.","family":"Cohn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee H.","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,7,10]]},"reference":[{"issue":"4","key":"79_CR1","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/S0035-9203(99)90106-2","volume":"93","author":"B Greenwood","year":"1999","unstructured":"Greenwood B. Manson lecture. Meningococcal meningitis in Africa. Trans R Soc Trop Med Hyg. 1999;93(4):341\u201353.","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"Suppl 2","key":"79_CR2","doi-asserted-by":"publisher","first-page":"B13","DOI":"10.1016\/j.vaccine.2009.04.062","volume":"27","author":"M LaForce","year":"2009","unstructured":"LaForce M, Ravenscroft N, Mamoudou D, Viviani S. Epidemic meningitis due to Group A Neisseria meningitidis in the African meningitis belt: a persistent problem with an imminent solution. Vaccine. 2009;27(Suppl 2):B13\u20139.","journal-title":"Vaccine"},{"issue":"5","key":"79_CR3","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1046\/j.1440-1754.2001.00722.x","volume":"37","author":"MG Baker","year":"2001","unstructured":"Baker MG, Martin DR, Kieft CE, Lennon D. A 10-year serogroup B meningococcal disease epidemic in New Zealand: descriptive epidemiology, 1991\u20132000. J Paediatr Child Health. 2001;37(5):S13\u20139.","journal-title":"J Paediatr Child Health"},{"issue":"17\u201318","key":"79_CR4","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1016\/j.vaccine.2005.01.063","volume":"23","author":"P Oster","year":"2005","unstructured":"Oster P, Lennon D, O\u2019Hallahan J, Mulholland K, Reid S, Martin D. MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain. Vaccine. 2005;23(17\u201318):2191\u20136.","journal-title":"Vaccine"},{"issue":"4","key":"79_CR5","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1086\/603552","volume":"49","author":"D Lennon","year":"2009","unstructured":"Lennon D, Jackson C, Wong S, Horsfall M, Stewart J, Reid S. Fast tracking the vaccine licensure process to control an epidemic of serogroup B meningococcal disease in New Zealand. Clin Infect Dis. 2009;49(4):597\u2013605.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"79_CR6","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1086\/649209","volume":"50","author":"AC Cohn","year":"2010","unstructured":"Cohn AC, MacNeil JR, Harrison LH, Hatcher C, Theodore J, Schmidt M, et al. Changes in Neisseria meningitidis disease epidemiology in the United States, 1998\u20132007: implications for prevention of meningococcal disease. Clin Infect Dis. 2010;50(2):184\u201391.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"79_CR7","first-page":"220","volume":"5","author":"CL Trotter","year":"2002","unstructured":"Trotter CL, Ramsay ME, Kaczmarski EB. Meningococcal serogroup C conjugate vaccination in England and Wales: coverage and initial impact of the campaign. Commun Dis Public Health. 2002;5(3):220\u20135.","journal-title":"Commun Dis Public Health"},{"issue":"RR-7","key":"79_CR8","first-page":"1","volume":"54","author":"OO Bilukha","year":"2005","unstructured":"Bilukha OO, Rosenstein N, Centers for Disease Control and Prevention. Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2005;54(RR-7):1\u201321.","journal-title":"MMWR Recomm Rep"},{"issue":"Suppl 2","key":"79_CR9","doi-asserted-by":"publisher","first-page":"B51","DOI":"10.1016\/j.vaccine.2009.04.063","volume":"27","author":"LH Harrison","year":"2009","unstructured":"Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine. 2009;27(Suppl 2):B51\u201363.","journal-title":"Vaccine"},{"issue":"18","key":"79_CR10","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1056\/NEJM200105033441807","volume":"344","author":"NE Rosenstein","year":"2001","unstructured":"Rosenstein NE, Perkins BA, Stephens DS, Popovic T, Hughes JM. Meningococcal disease. N Engl J Med. 2001;344(18):1378\u201388.","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"79_CR11","doi-asserted-by":"publisher","first-page":"A37","DOI":"10.1016\/j.vaccine.2007.04.038","volume":"25","author":"B Koumare","year":"2007","unstructured":"Koumare B, Ouedraogo-Traore R, Sanou I, Yada AA, Sow I, Lusamba PS, et al. The first large epidemic of meningococcal disease caused by serogroup W135, Burkina Faso, 2002. Vaccine. 2007;25(Suppl 1):A37\u201341.","journal-title":"Vaccine"},{"issue":"6","key":"79_CR12","doi-asserted-by":"publisher","first-page":"920","DOI":"10.3201\/eid1306.060940","volume":"13","author":"N Nathan","year":"2007","unstructured":"Nathan N, Rose AM, Legros D, Tiendrebeogo SR, Bachy C, Bjorlow E, et al. Meningitis serogroup W135 outbreak, Burkina Faso, 2002. Emerg Infect Dis. 2007;13(6):920\u20133.","journal-title":"Emerg Infect Dis"},{"issue":"5","key":"79_CR13","doi-asserted-by":"publisher","first-page":"e19513","DOI":"10.1371\/journal.pone.0019513","volume":"6","author":"I Delrieu","year":"2011","unstructured":"Delrieu I, Yaro S, Tamekloe TAS, Njanpop-Lafourcade BM, Tall H, Jaillard P, et al. Emergence of epidemic Neisseria meningitidis serogroup X meningitis in Togo and Burkina Faso. PLoS ONE. 2011;6(5):e19513.","journal-title":"PLoS ONE"},{"issue":"12","key":"79_CR14","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1046\/j.1360-2276.2003.01126.x","volume":"8","author":"S Djibo","year":"2003","unstructured":"Djibo S, Nicolas P, Alonso JM, Djibo A, Couret D, Riou JY, et al. Outbreaks of serogroup X meningococcal meningitis in Niger 1995\u20132000. Trop Med Int Health. 2003;8(12):1118\u201323.","journal-title":"Trop Med Int Health"},{"key":"79_CR15","unstructured":"Annual epidemiological report on communicable diseases in Europe. In: Control CfDPa, editor. Stockholm; 2009."},{"issue":"4","key":"79_CR16","first-page":"R49","volume":"7","author":"M Ramsay","year":"1997","unstructured":"Ramsay M, Kaczmarski E, Rush M, Mallard R, Farrington P, White J. Changing patterns of case ascertainment and trends in meningococcal disease in England and Wales. Commun Dis Rep CDR Rev. 1997;7(4):R49\u201354.","journal-title":"Commun Dis Rep CDR Rev"},{"issue":"2","key":"79_CR17","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1128\/jcm.32.2.323-330.1994","volume":"32","author":"DA Caugant","year":"1994","unstructured":"Caugant DA, Hoiby EA, Magnus P, Scheel O, Hoel T, Bjune G, et al. Asymptomatic carriage of Neisseria meningitidis in a randomly sampled population. J Clin Microbiol. 1994;32(2):323\u201330.","journal-title":"J Clin Microbiol"},{"issue":"Suppl 2","key":"79_CR18","doi-asserted-by":"publisher","first-page":"B64","DOI":"10.1016\/j.vaccine.2009.04.061","volume":"27","author":"DA Caugant","year":"2009","unstructured":"Caugant DA, Maiden MC. Meningococcal carriage and disease\u2014population biology and evolution. Vaccine. 2009;27(Suppl 2):B64\u201370.","journal-title":"Vaccine"},{"issue":"5","key":"79_CR19","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1136\/adc.85.5.391","volume":"85","author":"R Lakshman","year":"2001","unstructured":"Lakshman R, Jones I, Walker D, McMurtrie K, Shaw L, Race G, et al. Safety of a new conjugate meningococcal C vaccine in infants. Arch Dis Child. 2001;85(5):391\u20137.","journal-title":"Arch Dis Child"},{"issue":"20\u201322","key":"79_CR20","doi-asserted-by":"publisher","first-page":"2924","DOI":"10.1016\/S0264-410X(00)00528-4","volume":"19","author":"JC Bramley","year":"2001","unstructured":"Bramley JC, Hall T, Finn A, Buttery RB, Elliman D, Lockhart S, et al. Safety and immunogenicity of three lots of meningococcal serogroup C conjugate vaccine administered at 2, 3 and 4\u00a0months of age. Vaccine. 2001;19(20\u201322):2924\u201331.","journal-title":"Vaccine"},{"issue":"21","key":"79_CR21","doi-asserted-by":"publisher","first-page":"2795","DOI":"10.1001\/jama.283.21.2795","volume":"283","author":"JM MacLennan","year":"2000","unstructured":"MacLennan JM, Shackley F, Heath PT, Deeks JJ, Flamank C, Herbert M, et al. Safety, immunogenicity, and induction of immunologic memory by a serogroup C meningococcal conjugate vaccine in infants: a randomized controlled trial. JAMA. 2000;283(21):2795\u2013801.","journal-title":"JAMA"},{"issue":"24","key":"79_CR22","doi-asserted-by":"publisher","first-page":"2686","DOI":"10.1016\/S0264-410X(00)00050-5","volume":"18","author":"S Choo","year":"2000","unstructured":"Choo S, Zuckerman J, Goilav C, Hatzmann E, Everard J, Finn A. Immunogenicity and reactogenicity of a group C meningococcal conjugate vaccine compared with a group A\u00a0+\u00a0C meningococcal polysaccharide vaccine in adolescents in a randomised observer-blind controlled trial. Vaccine. 2000;18(24):2686\u201392.","journal-title":"Vaccine"},{"issue":"2","key":"79_CR23","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1097\/INF.0b013e31818a0237","volume":"28","author":"LA Jackson","year":"2009","unstructured":"Jackson LA, Jacobson RM, Reisinger KS, Anemona A, Danzig LE, Dull PM. A randomized trial to determine the tolerability and immunogenicity of a quadrivalent meningococcal glycoconjugate vaccine in healthy adolescents. Pediatr Infect Dis J. 2009;28(2):86\u201391.","journal-title":"Pediatr Infect Dis J"},{"issue":"2","key":"79_CR24","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1001\/jama.2007.29-c","volume":"299","author":"MD Snape","year":"2008","unstructured":"Snape MD, Perrett KP, Ford KJ, John TM, Pace D, Yu LM, et al. Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial. JAMA. 2008;299(2):173\u201384.","journal-title":"JAMA"},{"key":"79_CR25","first-page":"52","volume":"62","author":"Centers for Disease Control and Prevention","year":"2013","unstructured":"Centers for Disease Control and Prevention. Infant Meningococcal Vaccination: Advisory Committee on Immunization Practices (ACIP) Recommendations and Rationale. MMWR Morb Mortal Wkly Rep. 2013;62:52\u20134.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"9431","key":"79_CR26","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/S0140-6736(04)16725-1","volume":"364","author":"CL Trotter","year":"2004","unstructured":"Trotter CL, Andrews NJ, Kaczmarski EB, Miller E, Ramsay ME. Effectiveness of meningococcal serogroup C conjugate vaccine 4\u00a0years after introduction. Lancet. 2004;364(9431):365\u20137.","journal-title":"Lancet"},{"issue":"32","key":"79_CR27","doi-asserted-by":"publisher","first-page":"4097","DOI":"10.1016\/j.vaccine.2005.03.045","volume":"23","author":"A Larrauri","year":"2005","unstructured":"Larrauri A, Cano R, Garcia M, Mateo S. Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in Spain. Vaccine. 2005;23(32):4097\u2013100.","journal-title":"Vaccine"},{"key":"79_CR28","volume-title":"Meningococcal vaccine effectiveness","author":"JR MacNeil","year":"2012","unstructured":"MacNeil JR, Cohn AC. Meningococcal vaccine effectiveness. Boston: Pediatric Academic Society Annual Meeting; 2012."},{"issue":"9320","key":"79_CR29","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1016\/S0140-6736(02)08679-8","volume":"359","author":"MC Maiden","year":"2002","unstructured":"Maiden MC, Stuart JM. Carriage of serogroup C meningococci 1\u00a0year after meningococcal C conjugate polysaccharide vaccination. Lancet. 2002;359(9320):1829\u201331.","journal-title":"Lancet"},{"issue":"9251","key":"79_CR30","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/S0140-6736(00)03594-7","volume":"357","author":"ME Ramsay","year":"2001","unstructured":"Ramsay ME, Andrews N, Kaczmarski EB, Miller E. Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England. Lancet. 2001;357(9251):195\u20136.","journal-title":"Lancet"},{"issue":"7385","key":"79_CR31","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1136\/bmj.326.7385.365","volume":"326","author":"ME Ramsay","year":"2003","unstructured":"Ramsay ME, Andrews NJ, Trotter CL, Kaczmarski EB, Miller E. Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis. BMJ. 2003;326(7385):365\u20136.","journal-title":"BMJ"},{"issue":"5","key":"79_CR32","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1128\/CVI.00529-09","volume":"17","author":"H Campbell","year":"2010","unstructured":"Campbell H, Andrews N, Borrow R, Trotter C, Miller E. Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity. Clin Vaccine Immunol. 2010;17(5):840\u20137.","journal-title":"Clin Vaccine Immunol"},{"issue":"34","key":"79_CR33","first-page":"671","volume":"61","author":"CDC","year":"2012","unstructured":"CDC. National and state vaccination coverage among adolescents aged 13\u201317\u00a0years\u2014United States, 2011. MMWR Morb Mortal Wkly Rep. 2012;61(34):671\u20137.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"79_CR34","unstructured":"Clark TA, Stern EJ, Pondo T, Arnold K, Harrison L, Vello M, Hollick R, Mayer L, Schmink S, Hatcher C, Theodore J, Harcourt B, Dolan J, Stephens D, Messonnier N. The effect of quadrivalent (A, C, Y, W-135) meningococcal conjugate vaccine on serogroup-specific carriage of Neisseria meningitidis. 16th international pathogenic Neisseria conference, Rotterdam; 2008."},{"issue":"11","key":"79_CR35","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1086\/508776","volume":"43","author":"MD Snape","year":"2006","unstructured":"Snape MD, Kelly DF, Salt P, Green S, Snowden C, Diggle L, et al. Serogroup C meningococcal glycoconjugate vaccine in adolescents: persistence of bactericidal antibodies and kinetics of the immune response to a booster vaccine more than 3\u00a0years after immunization. Clin Infect Dis. 2006;43(11):1387\u201394.","journal-title":"Clin Infect Dis"},{"issue":"12","key":"79_CR36","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1086\/509619","volume":"194","author":"C Auckland","year":"2006","unstructured":"Auckland C, Gray S, Borrow R, Andrews N, Goldblatt D, Ramsay M, et al. Clinical and immunologic risk factors for meningococcal C conjugate vaccine failure in the United Kingdom. J Infect Dis. 2006;194(12):1745\u201352.","journal-title":"J Infect Dis"},{"issue":"9","key":"79_CR37","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1086\/344324","volume":"186","author":"R Borrow","year":"2002","unstructured":"Borrow R, Goldblatt D, Andrews N, Southern J, Ashton L, Deane S, et al. Antibody persistence and immunological memory at age 4\u00a0years after meningococcal group C conjugate vaccination in children in the United Kingdom. J Infect Dis. 2002;186(9):1353\u20137.","journal-title":"J Infect Dis"},{"issue":"2","key":"79_CR38","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1097\/01.inf.0000151029.58752.27","volume":"24","author":"MD Snape","year":"2005","unstructured":"Snape MD, Kelly DF, Green B, Moxon ER, Borrow R, Pollard AJ. Lack of serum bactericidal activity in preschool children two years after a single dose of serogroup C meningococcal polysaccharide-protein conjugate vaccine. Pediatr Infect Dis J. 2005;24(2):128\u201331.","journal-title":"Pediatr Infect Dis J"},{"issue":"33","key":"79_CR39","doi-asserted-by":"publisher","first-page":"4408","DOI":"10.1016\/j.vaccine.2009.05.047","volume":"27","author":"II Sakou","year":"2009","unstructured":"Sakou II, Tzanakaki G, Tsolia MN, Sioumala M, Barbouni A, Kyprianou M, et al. Investigation of serum bactericidal activity in childhood and adolescence 3\u20136\u00a0years after vaccination with a single dose of serogroup C meningococcal conjugate vaccine. Vaccine. 2009;27(33):4408\u201311.","journal-title":"Vaccine"},{"issue":"8","key":"79_CR40","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1128\/CVI.05655-11","volume":"19","author":"DA Ishola Jr","year":"2012","unstructured":"Ishola DA Jr, Borrow R, Findlow H, Findlow J, Trotter C, Ramsay ME. Prevalence of serum bactericidal antibody to serogroup C Neisseria meningitidis in England a decade after vaccine introduction. Clin Vaccine Immunol. 2012;19(8):1126\u201330.","journal-title":"Clin Vaccine Immunol"},{"issue":"6","key":"79_CR41","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1086\/500512","volume":"193","author":"DM Vu","year":"2006","unstructured":"Vu DM, Welsch JA, Zuno-Mitchell P, Dela Cruz JV, Granoff DM. Antibody persistence 3\u00a0years after immunization of adolescents with quadrivalent meningococcal conjugate vaccine. J Infect Dis. 2006;193(6):821\u20138.","journal-title":"J Infect Dis"},{"issue":"11","key":"79_CR42","doi-asserted-by":"publisher","first-page":"881","DOI":"10.4161\/hv.6.11.12849","volume":"6","author":"CJ Gill","year":"2010","unstructured":"Gill CJ, Baxter R, Anemona A, Ciavarro G, Dull P. Persistence of immune responses after a single dose of Novartis meningococcal serogroup A, C, W-135 and Y CRM-197 conjugate vaccine (Menveo(R)) or Menactra(R) among healthy adolescents. Hum Vaccine. 2010;6(11):881\u20137.","journal-title":"Hum Vaccine"},{"issue":"RR-2","key":"79_CR43","first-page":"1","volume":"62","author":"AC Cohn","year":"2013","unstructured":"Cohn AC, MacNeil JR, Clark TA, Ortega-Sanchez IR, Briere EZ, Meissner HC, et al. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2013;62(RR-2):1\u201328.","journal-title":"MMWR Recomm Rep"},{"key":"79_CR44","doi-asserted-by":"crossref","unstructured":"Marshall GS, Blatter M, Marchant C, Aris E, Mesaros N, Miller JM. Antibody persistence for up to 5 years after a fourth dose of haemophilus influenzae type B and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine (Hibmency-TT) given at 12\u201315\u00a0months of age. Pediatr Infect Dis J. 2013.","DOI":"10.1097\/INF.0b013e3182840e35"},{"key":"79_CR45","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/S1473-3099(11)70027-5","volume":"11","author":"F Caron","year":"2011","unstructured":"Caron F, du Chatelet IP, Leroy JP, Ruckly C, Blanchard M, Bohic N, et al. From tailor-made to ready-to-wear meningococcal B vaccines: longitudinal study of a clonal meningococcal B outbreak. Lancet Infect Dis. 2011;11:455\u201363.","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"79_CR46","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1073\/pnas.94.1.271","volume":"94","author":"JS Swartley","year":"1997","unstructured":"Swartley JS, Marfin AA, Edupuganti S, Liu LJ, Cieslak P, Perkins B, et al. Capsule switching of Neisseria meningitidis. Proc Natl Acad Sci USA. 1997;94(1):271\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"8","key":"79_CR47","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1086\/651505","volume":"201","author":"LH Harrison","year":"2010","unstructured":"Harrison LH, Shutt KA, Schmink SE, Marsh JW, Harcourt BH, Wang X, et al. Population structure and capsular switching of invasive Neisseria meningitidis isolates in the pre-meningococcal conjugate vaccine era\u2013United States, 2000\u20132005. J Infect Dis. 2010;201(8):1208\u201324.","journal-title":"J Infect Dis"},{"issue":"9","key":"79_CR48","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1086\/501371","volume":"193","author":"LH Harrison","year":"2006","unstructured":"Harrison LH, Jolley KA, Shutt KA, Marsh JW, O\u2019Leary M, Sanza LT, et al. Antigenic shift and increased incidence of meningococcal disease. J Infect Dis. 2006;193(9):1266\u201374.","journal-title":"J Infect Dis"},{"issue":"11","key":"79_CR49","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1086\/340414","volume":"185","author":"LW Mayer","year":"2002","unstructured":"Mayer LW, Reeves MW, Al-Hamdan N, Sacchi CT, Taha MK, Ajello GW, et al. Outbreak of W135 meningococcal disease in 2000: not emergence of a new W135 strain but clonal expansion within the electrophoretic type-37 complex. J Infect Dis. 2002;185(11):1596\u2013605.","journal-title":"J Infect Dis"},{"issue":"7","key":"79_CR50","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1086\/528996","volume":"197","author":"MR Moore","year":"2008","unstructured":"Moore MR, Gertz RE Jr, Woodbury RL, Barkocy-Gallagher GA, Schaffner W, Lexau C, et al. Population snapshot of emergent Streptococcus pneumoniae serotype 19A in the United States, 2005. J Infect Dis. 2008;197(7):1016\u201327.","journal-title":"J Infect Dis"},{"issue":"24","key":"79_CR51","doi-asserted-by":"publisher","first-page":"3710","DOI":"10.1016\/j.vaccine.2012.03.011","volume":"30","author":"SN Ladhani","year":"2012","unstructured":"Ladhani SN, Flood JS, Ramsay ME, Campbell H, Gray SJ, Kaczmarski EB, et al. Invasive meningococcal disease in England and Wales: implications for the introduction of new vaccines. Vaccine. 2012;30(24):3710\u20136.","journal-title":"Vaccine"},{"issue":"1","key":"79_CR52","doi-asserted-by":"publisher","first-page":"63","DOI":"10.3201\/eid1801.110901","volume":"18","author":"SN Ladhani","year":"2012","unstructured":"Ladhani SN, Lucidarme J, Newbold LS, Gray SJ, Carr AD, Findlow J, et al. Invasive meningococcal capsular group Y disease, England and Wales, 2007\u20132009. Emerg Infect Dis. 2012;18(1):63\u201370.","journal-title":"Emerg Infect Dis"},{"issue":"Suppl 2","key":"79_CR53","doi-asserted-by":"publisher","first-page":"B26","DOI":"10.1016\/j.vaccine.2011.12.032","volume":"30","author":"SA Halperin","year":"2012","unstructured":"Halperin SA, Bettinger JA, Greenwood B, Harrison LH, Jelfs J, Ladhani SN, et al. The changing and dynamic epidemiology of meningococcal disease. Vaccine. 2012;30(Suppl 2):B26\u201336.","journal-title":"Vaccine"},{"issue":"40","key":"79_CR54","first-page":"1023","volume":"54","author":"Guillain\u2013Barre syndrome among recipients of Menactra meningococcal conjugate vaccine\u2013United States, June\u2013July 2005","year":"2005","unstructured":"Guillain\u2013Barre syndrome among recipients of Menactra meningococcal conjugate vaccine\u2013United States, June\u2013July 2005. MMWR Morb Mortal Wkly Rep. 2005;54(40):1023\u20135.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"79_CR55","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1136\/bmj.38725.728472.BE","volume":"332","author":"J Tully","year":"2006","unstructured":"Tully J, Viner RM, Coen PG, Stuart JM, Zambon M, Peckham C, et al. Risk and protective factors for meningococcal disease in adolescents: matched cohort study. BMJ. 2006;332:445\u201350.","journal-title":"BMJ"},{"issue":"40","key":"79_CR56","first-page":"1391","volume":"60","author":"Recommendation of the Advisory Committee on Immunization Practices (ACIP)","year":"2011","unstructured":"Recommendation of the Advisory Committee on Immunization Practices (ACIP) for use of quadrivalent meningococcal conjugate vaccine (MenACWY-D) among children aged 9 through 23\u00a0months at increased risk for invasive meningococcal disease. MMWR Morb Mortal Wkly Rep. 2011;60(40):1391\u20132.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"10","key":"79_CR57","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/S1473-3099(12)70168-8","volume":"12","author":"RT Novak","year":"2012","unstructured":"Novak RT, Kambou JL, Diomande FV, Tarbangdo TF, Ouedraogo-Traore R, Sangare L, et al. Serogroup A meningococcal conjugate vaccination in Burkina Faso: analysis of national surveillance data. Lancet Infect Dis. 2012;12(10):757\u201364.","journal-title":"Lancet Infect Dis"},{"key":"79_CR58","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1093\/cid\/cis892","volume":"56","author":"PA Kristiansen","year":"2013","unstructured":"Kristiansen PA, Diomande F, Ba AK, Sanou I, Ouedraogo AS, Ouedraogo R, et al. Impact of the serogroup A meningococcal conjugate vaccine, MenAfriVac, on carriage and herd immunity. Clin Infect Dis. 2013;56:354\u201363.","journal-title":"Clin Infect Dis"},{"issue":"8","key":"79_CR59","first-page":"2402","volume":"38","author":"MLC Tondella","year":"2000","unstructured":"Tondella MLC, Popovic T, Rosenstein NE, Lake DB, Mayer L, Perkins B, et al. Distribution of Neisseria meningitidis serogroup B serosubtypes and serotypes circulating in the United States. J Clin Microbiol. 2000;38(8):2402\u20137.","journal-title":"J Clin Microbiol"},{"issue":"4","key":"79_CR60","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1086\/315833","volume":"182","author":"CT Sacchi","year":"2000","unstructured":"Sacchi CT, Whitney AM, Popovic T, Beall DS, Reeves MW, Plikaytis BD, et al. Diversity and prevalence of PorA types in Neisseria meningitidis serogroup B in the United States, 1992\u20131998. J Infect Dis. 2000;182(4):1169\u201376.","journal-title":"J Infect Dis"},{"issue":"Pt 4","key":"79_CR61","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1099\/jmm.0.45855-0","volume":"54","author":"D Vicente","year":"2005","unstructured":"Vicente D, Esnal O, Michaus L, Lopez de Goicoechea MJ, Cisterna R, Perez-Trallero E. Prevalence of genosubtypes (PorA types) of serogroup B invasive meningococcus in the north of Spain from 2000 to 2003. J Med Microbiol. 2005;54(Pt 4):381\u20134.","journal-title":"J Med Microbiol"},{"key":"79_CR62","unstructured":"Jansen KU, McNeil LK, Dragalin V, Anderson AS, Hoiseth SK, Arora A, et al. Bivalent recombinant LP2086 vaccine to provide broad protection against Neisseria meningitidis B disease: immunological correlates of protection and how to assess coverage against invasive MnB strains. 16th International pathogenic Neisseria conference, Rotterdam; 2008."},{"issue":"37","key":"79_CR63","doi-asserted-by":"publisher","first-page":"6086","DOI":"10.1016\/j.vaccine.2010.06.083","volume":"28","author":"HQ Jiang","year":"2010","unstructured":"Jiang HQ, Hoiseth SK, Harris SL, McNeil LK, Zhu D, Tan C, et al. Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease. Vaccine. 2010;28(37):6086\u201393.","journal-title":"Vaccine"},{"issue":"10","key":"79_CR64","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1086\/656741","volume":"51","author":"J Findlow","year":"2010","unstructured":"Findlow J, Borrow R, Snape MD, Dawson T, Holland A, John TM, et al. Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. Clin Infect Dis. 2010;51(10):1127\u201337.","journal-title":"Clin Infect Dis"},{"issue":"9","key":"79_CR65","doi-asserted-by":"publisher","first-page":"e1302","DOI":"10.1371\/journal.pntd.0001302","volume":"5","author":"R Pajon","year":"2011","unstructured":"Pajon R, Fergus AM, Koeberling O, Caugant DA, Granoff DM. Meningococcal factor H binding proteins in epidemic strains from Africa: implications for vaccine development. PLoS Negl Trop Dis. 2011;5(9):e1302.","journal-title":"PLoS Negl Trop Dis"},{"issue":"9","key":"79_CR66","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1086\/597806","volume":"199","author":"PT Beernink","year":"2009","unstructured":"Beernink PT, Caugant DA, Welsch JA, Koeberling O, Granoff DM. Meningococcal factor H-binding protein variants expressed by epidemic capsular group A, W-135, and X strains from Africa. J Infect Dis. 2009;199(9):1360\u20138.","journal-title":"J Infect Dis"},{"issue":"45","key":"79_CR67","doi-asserted-by":"publisher","first-page":"19490","DOI":"10.1073\/pnas.1013758107","volume":"107","author":"J Donnelly","year":"2010","unstructured":"Donnelly J, Medini D, Boccadifuoco G, Biolchi A, Ward J, Frasch C, et al. Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proc Natl Acad Sci USA. 2010;107(45):19490\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"10","key":"79_CR68","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1128\/CVI.00202-12","volume":"19","author":"BD Plikaytis","year":"2012","unstructured":"Plikaytis BD, Stella M, Boccadifuoco G, DeTora LM, Agnusdei M, Santini L, et al. Interlaboratory standardization of the sandwich enzyme-linked immunosorbent assay designed for MATS, a rapid, reproducible method for estimating the strain coverage of investigational vaccines. Clin Vaccine Immunol. 2012;19(10):1609\u201317.","journal-title":"Clin Vaccine Immunol"},{"issue":"6","key":"79_CR69","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1001\/jama.2012.85","volume":"307","author":"N Gossger","year":"2012","unstructured":"Gossger N, Snape MD, Yu LM, Finn A, Bona G, Esposito S, et al. Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial. JAMA. 2012;307(6):573\u201382.","journal-title":"JAMA"},{"issue":"29\u201330","key":"79_CR70","doi-asserted-by":"publisher","first-page":"4739","DOI":"10.1016\/j.vaccine.2011.04.092","volume":"29","author":"X Wang","year":"2011","unstructured":"Wang X, Cohn A, Comanducci M, Andrew L, Zhao X, MacNeil JR, et al. Prevalence and genetic diversity of candidate vaccine antigens among invasive Neisseria meningitidis isolates in the United States. Vaccine. 2011;29(29\u201330):4739\u201344.","journal-title":"Vaccine"},{"issue":"23","key":"79_CR71","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1016\/j.vaccine.2013.03.034","volume":"31","author":"H Christensen","year":"2013","unstructured":"Christensen H, Hickman M, Edmunds WJ, Trotter CL. Introducing vaccination against serogroup B meningococcal disease: an economic and mathematical modelling study of potential impact. Vaccine. 2013;31(23):2638-46","journal-title":"Vaccine"},{"key":"79_CR72","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/B978-1-4557-0090-5.00029-X","volume-title":"Vaccines","author":"DM Granoff","year":"2013","unstructured":"Granoff DM, Pelton S, Harrison LH. Meningococcal vaccines. In: Plotkin SA, Orenstein WA, Offit PA, editors. Vaccines. 6th ed. Philadelphia: Saunders Elsevier; 2013. p. 388\u2013418.","edition":"6"},{"key":"79_CR73","doi-asserted-by":"publisher","unstructured":"Jacobson RM, Jackson LA, Reisinger K, Izu A, Odrljin T, Dull T. Antibody persistence and response to a booster dose of a quadrivalent conjugate vaccine for meningococcal disease in adolescents. Pediatr Infect Dis J. doi:10.1097\/INF.0b013e318279ac38.","DOI":"10.1097\/INF.0b013e318279ac38"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-013-0079-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-013-0079-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-013-0079-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-013-0079-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T11:04:21Z","timestamp":1744715061000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-013-0079-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7]]},"references-count":73,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["79"],"URL":"https:\/\/doi.org\/10.1007\/s40265-013-0079-2","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,7]]},"assertion":[{"value":"10 July 2013","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}